World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Although COVID-19 has slowed the growth of drug sales, the oncology market’s total growth is driven by the targeted drugs in oncology. ” The U.S. ” The U.S.

Pharma Companies 210

Pharma Companies Marketing Drugs Production 210

pharmaphorum

AUGUST 25, 2022

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years. and 18,3 months, respectively.

Antibody 98

Antibody Marketing Drugs Medicine 98

pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

Drugs 110

Drugs FDA Approval Trials Marketing 110

Drug Discovery World

OCTOBER 31, 2023

UK regulatory authorities have approved the first trial of a gene therapy for young children with Hunter syndrome. The drug was developed over eight years by Brian Bigger, Professor of Cell and Gene Therapy at The University of Manchester. The modified HSCs are then infused back into the patient to engraft in the bone marrow.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

XTalks

JANUARY 19, 2024

These include isotopes like iodine-131 for treating thyroid cancer or yttrium-90 for targeted radiotherapy in certain cancers. In 2023, there have been pivotal trends shaping the landscape and application of alpha emitter therapy. Therapeutic radiopharmaceuticals are particularly used in the treatment of cancer.

DNA 66

DNA Radiology FDA Approval Development 66

pharmaphorum

DECEMBER 23, 2021

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. After EGFR therapy fails, platinum-based chemo has limited efficacy, generally preventing disease progression or death for between four and six months.

Drugs 71

Drugs Antibody Clinical Trials Clinical Trials 71

XTalks

APRIL 18, 2024

The Elecsys pTau217 assay is being developed for various use case scenarios, including clinical trials or determining eligibility for approved disease-modifying therapies. The approval of amyloid-beta-targeting therapies like Leqembi and recently discontinued Aduhelm (aducanumab) have come with controversy around their clinical effectiveness.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

Drug Discovery World

OCTOBER 31, 2022

The last month has seen huge strides forward in our understanding of cancers, particularly in how they develop resistance to therapies and how we can ‘outsmart’ them using gene editing or different therapeutic pathways, but also how we can better target drugs to individuals and accurately predict treatment outcomes.

Drugs 52

Drugs Research Gene Editing Protein 52

XTalks

FEBRUARY 27, 2024

Iovance Biotherapeutics’ Amtagvi (lifileucel) won US Food and Drug Administration (FDA) approval last week for the treatment of advanced melanoma, making it the first individualized tumor-infiltrating lymphocyte (TIL) therapy and the first T-cell therapy for a solid tumor to win US regulatory approval.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

pharmaphorum

JULY 25, 2022

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.

Antibody 52

Antibody Medicine Drugs Trials 52

pharmaphorum

APRIL 27, 2022

The coveted status has been awarded to the HER2-targeting antibody-drug conjugate (ADC) on the back of the DESTINY-Breast04 trial results, unveiled in February, which involved patients with HER2-low, unresectable and/or metastatic breast cancer previously treated with one to two prior lines of chemotherapy.

Sales 58

Sales Drugs Antibody Licensing 58

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based

Development 52

Development Drugs Clinical Development Antibody 52

Drug Discovery World

NOVEMBER 28, 2023

An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications. This paper strongly supports further study of USP30 inhibition as a potential disease-modifying therapy for PD.”

In-Vivo 52

In-Vivo Protein Drugs Research 52

Drug Discovery World

OCTOBER 28, 2022

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses. . Click’ chemistry used to tag proteins made by cancer cells . This week’s top stories: . Could mRNA become a ‘universal’ Covid-19 treatment? . Radioactive implant ‘completely eliminated’ tumours .

Drugs 52

Drugs Antibody Protein RNA 52

XTalks

FEBRUARY 27, 2024

The US Food and Drug Administration (FDA) has approved a number of new rare disease drugs in recent years, including gene therapies. This focus continues, with 20 out of 37 novel drug approvals targeted towards rare diseases​ in 2022 and around 24 out of 55 in 2023.

Research 59

Research Drugs Gene Therapy Clinical Trials 59

Rethinking Clinical Trials

JUNE 14, 2023

When evaluating when and how RWE studies complement RCTs, it’s important to consider the target trial design that would best match the need or questions of the end users. How do we teach our students and colleagues how to use the target trial framework and use these emulation approaches to advance our comparative effectiveness studies?

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

pharmaphorum

APRIL 5, 2022

The therapy is a bispecific T cell engager (BiTE) molecule, consisting of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes. The post Immunocore gets EU nod for TCR cancer therapy Kimmtrak appeared first on. ” Image by Pexels from Pixabay .

Sales 52

Sales Protein Drugs Trials 52

pharmaphorum

AUGUST 21, 2022

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. Auvelity isn’t the first NMDA-targeting antidepressant to reach the market.

Drugs 98

Drugs FDA Approval Production Marketing 98

pharmaphorum

APRIL 20, 2021

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. . The post NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta appeared first on. Novartis took ownership of the drug in 2015.

Sales 110

Sales Medicine Drugs Marketing 110

The Pharma Data

JANUARY 31, 2021

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. The trimeric S protein of SARS-CoV-2 is responsible for binding to host cell surface receptor ACE2 and subsequent viral entry, making it the primary target antigen for vaccine development.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

DECEMBER 21, 2022

The past year has been a strong one for life sciences industries, from pivotal gene therapy approvals to continued innovations in the biotech and medical device spaces. Gene Therapy Approvals. Bluebird bio is a notable mention as it secured FDA approvals for two of its gene therapies, Zynteglo and Skysona.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

The Pharma Data

MARCH 23, 2022

Drugs that target polymerase could potentially treat Ebola virus infections and save lives. Their investigation reveals that an experimental drug that targets GSPT1 for degradation can also halt Ebola virus infection in human cells. But targeting Ebola virus polymerase has proven tough. The problems with Ebola polymerase.

Protein 52

Protein Genome Genomics Research 52

XTalks

JUNE 8, 2021

Novartis’ Zolgensma (onasemnogene abeparvovec) gene therapy has been making significant strides as of late, including dosing of the first Spinal Muscular Atrophy (SMA) patient with the treatment in the UK last week. With a price tag of over $2.5 With a price tag of over $2.5 Zolgensma Gene Therapy: START Trial.

Gene Therapy 110

Gene Therapy Gene Protein Trials 110

pharmaphorum

OCTOBER 29, 2021

Gilead’s Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan) will be paired with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) in a new phase 3 trial in previously-untreated subjects with locally advanced or metastatic TNBC. billion for the full year. While its headline revenue of $7.4

Trials 52

Trials Sales FDA Approval Production 52

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

Drug Discovery World

NOVEMBER 13, 2023

On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against membrane protein targets, engineering bispecific antibodies, next-generation immunotherapies, protein stability and formulation, and protein process development.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

DECEMBER 3, 2020

Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. The trimeric S protein of SARS-CoV-2 is responsible for binding to host cell surface receptor ACE2 and subsequent viral entry, making it the primary target antigen for vaccine development.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

JANUARY 28, 2022

Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose. It targets gp100, which is a glycoprotein expressed in melanocytes and a tumor-associated antigen in melanoma. The median treatment time is about 23 weeks (or 5.3 months), so the average cost per patient will be approximately $400,000.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

Rethinking Clinical Trials

DECEMBER 6, 2022

The TARGET-HF-DM is a pragmatic multicenter randomized controlled trial held at 6 sites in the U.S. Adherence to medical therapy was not measurably different between the arms. Medication adherence can be a barrier to effectiveness. This trial turned out to be more challenging than anticipated. One pays more than another.

Trials 130

Trials Clinical Trials Clinical Trials Compliance 130

The Pharma Data

NOVEMBER 15, 2020

Peng Liang , Founder and Chief Scientific Officer of Clover and inventor of the Trimer-Tag© technology, says, “A successful vaccine that can truly modulate the course of the COVID-19 pandemic must have four essential characteristics: safety, efficacy, scalability of manufacturing, and speed. About Cytiva.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

Drug Discovery World

NOVEMBER 9, 2023

Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’. These include: Chairperson Keyt on: ‘IgM antibodies as receptor cross-linking agents for DR-5 and other TNF targets’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 130

Antibody DNA Development Vaccination 130

The Pharma Data

JANUARY 31, 2021

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. The trimeric S protein of SARS-CoV-2 is responsible for binding to host cell surface receptor ACE2 and subsequent viral entry, making it the primary target antigen for vaccine development.

Vaccination 52

Vaccination Vaccine Trials Protein 52

Delveinsight

FEBRUARY 9, 2021

Breyanzi, BMS’ Blood Cancer CAR-T Therapy Receives FDA Nod. Breyanzi targets CD19, a protein that is highly expressed on the surface of B cells, which remain there following the transformation of these cells from normal to malignant. Ukoniq’s approval was backed by Phase 2 UNITY-NHL Trial (NCT02793583).

FDA Approval 52

FDA Approval Marketing Research Protein 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. There are several different types of immunotherapies, including chemical inhibitors, cell-based therapies (i.e. Selective Targeting with Cue Biopharma’s Immune Biologics.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

OCTOBER 26, 2021

The treatment came with an initial price tag of $39,000 per vial, which amounts to a total of $575,00 each year. Related: Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA. Givlaari reduces ALAS1 levels through RNA interference-mediated gene silencing, which targets ALAS1 mRNA.

Gene Silencing 98

Gene Silencing Gene Clinical Trials Clinical Trials 98

XTalks

OCTOBER 12, 2022

MRI may also be used to evaluate drug dosing regimens, to gain insight about the mechanism of drug action, and to collect imaging biomarker data which could provide an earlier indication of response to therapy than clinical outcomes. An Example of an Anti-Angiogenic Therapy in Oncology. Why Image Vascular Perfusion?

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93